Table 3 Response and survival following CL56 and subsequent response to further hormone therapy
Median no. of cycles: | 2 (range 1–6) |
Response to CL56 | |
CR | 1 |
PR | 2 |
SD | 17 |
PD | 12 |
NE | 5 |
Response rate | |
3/32 (10%) | |
Stabilisation rate (SD or better) | |
20/32 (63%) | |
Symptomatic improvement (24 evaluable) | |
No | 13 |
Yes | 11 |
Alk Phos response by week 8 (14 evaluable) | |
No | 11 |
Yes | 3 |
Median survival | 7.1 months (95% CI 6.2–8.0) |
Median time to progression | 3.6 months (95% CI 2.3–4.9) |
PF at 6 months | 5/37 |
Median survival following AI | 23.5 months (95% CI 17.2–29.8) |
Post-CL56 hormones | |
Yes | 17 |
Response to post-CL56 hormone therapy | |
Yes | 9 |
>50% | 3 |
